{"meshTags":["Melanoma","Thigh","Skin Neoplasms","Middle Aged","Interferon-alpha","Acute Disease","Female","Recombinant Proteins","Humans","Chemotherapy, Adjuvant","Rhabdomyolysis"],"meshMinor":["Melanoma","Thigh","Skin Neoplasms","Middle Aged","Interferon-alpha","Acute Disease","Female","Recombinant Proteins","Humans","Chemotherapy, Adjuvant","Rhabdomyolysis"],"genes":["interferon","Interferon alfa-2b","interferon alfa-2b","interferon alfa-2b","interferon alfa-2b","interferon","interferon","creatine kinase"],"organisms":["9606","9606"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"Interferon alfa-2b is a treatment option for select patients with stage 3 melanoma.\nTo highlight the potential complication of acute rhabdomyolysis from interferon alfa-2b in this patient population.\nWe present a case of a 63-year-old female with stage IIIc melanoma who developed acute rhabdomyolysis after completing 2 of 4 weeks of induction with high-dose interferon alfa-2b. She recovered after hydration with intravenous fluids and discontinuation of interferon alfa-2b.\nReview of the literature revealed eight cases of reported rhabdomyolysis triggered by interferon use, including four cases of melanoma.\nIn patients treated with interferon, especially at high doses, screening for creatine kinase and myoglobinuria should be performed if the patient develops symptoms suggestive of acute rhabdomyolysis.","title":"Acute rhabdomyolysis as a complication of interferon treatment for stage IIIc melanoma.","pubmedId":"25008446"}